MustGrow Biologics has launched its campaign on the Investing News Network’s Cannabis channel.

MustGrow Biologics is an agricultural biotech company that is developing and commercializing its unique natural biofumigant, which acts as a fertilizer, nematocide and fungicide. MustGrow’s product is based on brassica plants, a genus of the mustard family.


The company’s target markets are the fruit, vegetable and cannabis industries. Its product has been tested on fruits and vegetables in 110 different trials, and has proven that it can protect plants from fungal diseases and pests. The company is currently working on determining the product’s efficacy for cannabis crops. Having first created a granular product, MustGrow is now developing a liquid version that can be easily delivered to plants via existing drip systems.

MustGrow Biologics’ company highlights include the following:

  • Proprietary natural, organic biofumigation solution for addressing pests and diseases in cannabis, and fruit and vegetable crops
  • 110 trials conducted in fruit and vegetables, determining protection from a number of soil borne pets and fungal diseases including nematodes, pythium and fusarium.  
  • ETA approval across all key US states as a fertilizer and pesticide (currently limited to fertilizer in California)
  • Health Canada designation as a fruit and vegetable fertilizer and pesticide
  • Developing liquid format of tested product in response to market demand
  • Growing global biopesticide crop protection market potentially worth $7 billion by 2019
  • Planned CSE listing 
  • Experienced management team supported by director Tom Flow, who brings vast cannabis sector experience

Click here to see the educational profile for MustGrow Biologics and to request an investor presentation.

In the cannabis space this week, retailer Fire & Flower Holdings (TSX:FAF,OTCQX:FFLWF) told investors it will be entering the US market through a novel strategic action.

Meanwhile, two longstanding cannabis partners ended their relationship.

Keep reading... Show less

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less